FREEHOLD, NJ / ACCESSWIRE / February 23, 2016 / MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “company” or “Medifirst”) would like to follow up and update its shareholders on the progress of its 510(k) submission including the request for more information from the Food and Drug Administration (FDA). As part of the review process, when more information is requested, the FDA allows the company 180 days to respond. Commented CEO Bruce J. Schoengood, “We are pleased to announce that we anticipate completion of the response to the FDA’s request for more information by the end of March.” To facilitate the response, Medifirst has engaged an industry leading laboratory and testing facility that employs over 38,000 people in 1,000 locations in over 100 countries. They hold extensive global accreditations, recognitions, and agreements and their knowledge and expertise is in overcoming regulatory, market, and supply chain hurdles. Medifirst has engaged this company to perform a test known as the IEC 60601-1-2 Medical Electrical Equipment Part 1-2: General Requirements for Safety: Electromagnetic Compatibility.
Continued CEO Schoengood, “Additional testing has already been completed and other requests will be completed in the upcoming days and weeks, including technical and informational revisions and updates to the product’s manuals and labels. We are very pleased to be working with one of the biggest labs in the industry and we are excited to be aggressively responding to the FDA request for more information. We appreciate the support and patience of our shareholders and the company will continue to update its shareholders on a regular basis.” Medifirst believes that its laser devices are very unique and offer an easy-to-use, mobile, affordable and effective product for many different health care professionals. The Time Machine Laser System can serve to enhance the current treatment protocols of various health care professionals, as well as produce additional revenue streams from the treatment range Medifirst believes The Time Machine Infrared Laser System is capable of delivering. Please visit www.medifirstsolutions.com and the Medifirst social media pages for more information.
About the Lasers
Medical Lasers Manufacturer, Inc. (“MLM”), a Medifirst subsidiary, will specialize in producing high quality diode-pumped solid-state lasers. The laser division, including products and treatment programs, will be operated out of MLM. The company’s focus is to help patients with specific cosmetic skin conditions, as well as relief of muscle and joint pain and muscle spasm and inflammation. MLM’s manufacturer consists of a group of engineers with decades of experience in laser research and manufacturing that have been providing customized laser products to a wide variety of universities and labs.Driven by the huge demand for minimally invasive skin and pain treatments, the global market for medical and therapeutic lasers have been estimated to grow as high as to $4 billion in 2015.
About Medifirst Solutions, Inc.
Medifirst Solutions, Inc. is a Nevada corporation that is headquartered in New Jersey. The company seeks innovative medical and healthcare products and technologies which are targeted to both medical and healthcare professionals, as well as everyday consumers. Medifirst is developing and establishing both consumer and professional medical cliental that can serve as a pipeline that will allow for distribution of future products and services. For more details visit www.medifirstsolutions.com for more information.
Forward-Looking Statements: The statements in this press release that relate to the company’s expectations with regard to the future impact on the company’s results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control. Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission. Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company’s actual results may differ materially from expected results. We make no commitment to disclose any subsequent revisions to forward-looking statements.
SOURCE: Medifirst Solutions, Inc.